Akesobio

Akeso, Inc.

康方生物科技(開曼)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

AKESO GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS FOR 伊喜寧® TO JUMPCAN PHARMACEUTICAL

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that Akeso Biopharma Co., Ltd. (中山康方生物醫藥有限公司) and AD Pharmaceuticals Co., Ltd. (康融東方(廣東)醫藥有限公司) (collectively referred to hereinafter as "**Akeso**"), both being indirect wholly-owned subsidiaries of the Company, have recently entered into an exclusive commercialization rights agreement with JumpCan Pharmaceutical Group Co., Ltd. (濟川藥業集團有限公司) and Jiangsu Jiyuan Pharmaceutical Co., Ltd. (江蘇濟源醫藥有限公司) (collectively referred to hereinafter as "**JumpCan Pharmaceutical**"), both being wholly-owned subsidiaries of Hubei JumpCan Pharmaceutical Co., Ltd. (湖北濟川藥業股份有限公司). Pursuant to the agreement, Akeso has granted JumpCan Pharmaceutical the exclusive commercialization rights within the People's Republic of China (excluding Hong Kong, the Macao Special Administrative Region, and Taiwan) for the Company's independently developed and approved product, 伊喜寧® (ebronucimab injection), during the term of the collaboration. Under this collaboration, Akeso will receive a license fee of RMB80 million (tax inclusive) and milestone payments of up to RMB10 million (tax inclusive) from JumpCan Pharmaceutical. JumpCan Pharmaceutical will be responsible for the commercialization and sales of 伊喜寧® in the authorized market.

ABOUT 伊喜寧®

伊喜寧® (ebronucimab injection) is a novel PCSK9 monoclonal antibody independently developed by the Company. It was approved for market launch in September 2024 for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia with established atherosclerotic cardiovascular disease. Currently, 伊喜寧® has been included in the latest National Reimbursement Drug List (NRDL) and is strongly recommended in the Chinese Expert Consensus on Comprehensive Management of Lipid-related Cardiovascular Risks (2025 Edition) and the County-level Guidelines for Rational Drug Use and Comprehensive Management of Dyslipidemia (2025 Edition).

伊喜寧® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma. Previous studies have demonstrated that administering PCSK9 monoclonal antibody therapy alongside statin background treatment can significantly reduce cholesterol levels in human body and lower the risk of heart attack and stroke in patients. Phase III clinical studies have shown that 伊喜寧® exhibits excellent clinical efficacy for patients stratified as ultra-high-risk, very high-risk, high-risk and moderate-to-low risk, as well as for patients regardless of their baseline LDL-C status, providing a new option for the clinical treatment of hypercholesterolemia and the long-term control of cardiovascular risks.

ABOUT AD PHARMACEUTICALS CO., LTD.

AD Pharmaceuticals Co., Ltd. (康融東方(廣東)醫藥有限公司) is an innovative biopharmaceutical company integrating antibody drug development, manufacturing, and sales. AD Pharmaceuticals is an indirect wholly-owned subsidiary of the Company.

ABOUT JUMPCAN PHARMACEUTICAL

Hubei JumpCan Pharmaceutical Co., Ltd. (湖北濟川藥業股份有限公司, stock code: 600566.SS) is one of the leading pharmaceutical enterprises in China. It has built a strong presence in the domestic pharmaceutical market over the years, featuring strong channels and networks, as well as a commercialization team with deep market insights and broad experience. JumpCan Pharmaceutical Group Co., Ltd. (濟川藥業集團有限公司) and Jiangsu Jiyuan Pharmaceutical Co., Ltd. (江蘇濟源醫藥有限公司) are wholly-owned subsidiaries of Hubei JumpCan Pharmaceutical Co., Ltd.

By order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, February 3, 2026

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.